Pulmatrix Inc
PULM5.360USD
+0.027+0.51%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
19.58MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Pulmatrix Inc Unternehmen
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Unternehmensinformationen
BörsenkürzelPULM
Name des UnternehmensPulmatrix Inc
IPO-datumMar 21, 2014
CEOMr. Peter B. Ludlum
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeMar 21
Addresse945 Concord Street
StadtFRAMINGHAM
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl01701
Telefon18883554440
Websitehttps://www.pulmatrix.com/
BörsenkürzelPULM
IPO-datumMar 21, 2014
CEOMr. Peter B. Ludlum
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
7.83K
--
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Independent Director
Independent Director
4.16K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
Independent Director
Independent Director
4.16K
--
Mr. Anand Varadan
Mr. Anand Varadan
Independent Director
Independent Director
3.32K
--
Mr. Timothy McCarthy
Mr. Timothy McCarthy
Investor Relations
Investor Relations
--
--
Mr. Peter B. Ludlum
Mr. Peter B. Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer
Interim Chief Executive Officer and Interim Chief Financial Officer
--
--
Dr. Richard Batycky, Ph.D.
Dr. Richard Batycky, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
7.83K
--
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Independent Director
Independent Director
4.16K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
Independent Director
Independent Director
4.16K
--
Mr. Anand Varadan
Mr. Anand Varadan
Independent Director
Independent Director
3.32K
--
Mr. Timothy McCarthy
Mr. Timothy McCarthy
Investor Relations
Investor Relations
--
--
Mr. Peter B. Ludlum
Mr. Peter B. Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer
Interim Chief Executive Officer and Interim Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, May 29
Aktualisiert: Thu, May 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Renaissance Technologies LLC
2.98%
BlackRock Institutional Trust Company, N.A.
1.50%
SBI Securities Co., Ltd.
1.43%
The Vanguard Group, Inc.
1.16%
Geode Capital Management, L.L.C.
1.11%
Other
91.81%
Aktionäre
Aktionäre
Anteil
Renaissance Technologies LLC
2.98%
BlackRock Institutional Trust Company, N.A.
1.50%
SBI Securities Co., Ltd.
1.43%
The Vanguard Group, Inc.
1.16%
Geode Capital Management, L.L.C.
1.11%
Other
91.81%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
3.00%
Investment Advisor/Hedge Fund
2.88%
Investment Advisor
1.53%
Research Firm
1.43%
Individual Investor
0.66%
Other
90.49%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
32
347.44K
9.51%
-94.22K
2025Q1
34
346.08K
9.48%
-117.47K
2024Q4
30
329.25K
9.01%
-61.75K
2024Q3
31
276.56K
7.57%
-108.94K
2024Q2
31
263.58K
7.22%
-1.04M
2024Q1
33
261.48K
7.16%
-1.04M
2023Q4
39
316.17K
8.66%
-1.16M
2023Q3
44
516.38K
14.50%
-1.18M
2023Q2
48
580.98K
16.42%
-1.18M
2023Q1
54
668.56K
18.82%
-1.15M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Renaissance Technologies LLC
108.92K
2.98%
-200.00
-0.18%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
54.90K
1.5%
--
--
Mar 31, 2025
SBI Securities Co., Ltd.
52.36K
1.43%
-13.83K
-20.90%
Mar 31, 2025
The Vanguard Group, Inc.
42.40K
1.16%
+7.32K
+20.87%
Mar 31, 2025
Geode Capital Management, L.L.C.
40.37K
1.11%
+3.50K
+9.48%
Mar 31, 2025
State Street Global Advisors (US)
13.95K
0.38%
--
--
Mar 31, 2025
Higgins (Michael J)
7.83K
0.21%
--
--
May 01, 2025
Dimensional Fund Advisors, L.P.
6.25K
0.17%
+1.36K
+27.72%
May 31, 2025
Batycky (Richard P. Ph.D.)
4.69K
0.13%
--
--
May 01, 2025
Bazemore (Todd M)
4.16K
0.11%
--
--
May 01, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Datum
Art
Verhältnis
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
